Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL407952 | 0.99 | CYP19A1 (0.57) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8805939 | 0.92 | CYP19A1 (0.63) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11759493 | 0.91 | CYP19A1 (0.62) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10247118 | 0.87 | CYP11B1 (0.58) | CYP11B1CYP11B2 | |
| SCHEMBL10927212 | 0.87 | CYP11B1 (0.53) | CYP19A1CYP11B1 | |
| SCHEMBL10247196 | 0.86 | AGER (0.47) | — | |
| SCHEMBL411443 | 0.86 | HMOX1 (0.57) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8803353 | 0.86 | CYP19A1 (0.56) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8804330 | 0.86 | CYP11B1 (0.44) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL409343 | 0.86 | ALDH1A1 (0.59) | CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | claimed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| EP-0492474-B1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX INC (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5158949-A | 1,3-DIOXOLANE DERIVATIVES AS CHOLESTEROL-LOWERING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0492474-A1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX (U.S.A.) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4518607-A | FUNGICIDES, BACXTERICIDES AND ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1985-05-21 | — | — | US | disclosed |
| EP-0005980-B1 | DERIVATIVES OF SUBSTITUTED N-ALKYL IMIDAZOLES, THEIR PREPARATION AND THESE COMPOUNDS FOR PHARMACEUTICAL USE | SYNTEX (U.S.A.) INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| US-4272545-A | FUNGICIDES, BACTERICIDE, ANTIPROTOZOA, SPERMATOCIDE | SYNTEX (U.S.A.) INC. (US) | 1981-06-09 | — | — | US | disclosed |
| US-4213991-A | BACTERICIDES, FUNGICIDES, ANTIPROTOZOA | SYNTEX (U.S.A.) INC. (US) | 1980-07-22 | — | — | US | disclosed |
| EP-0005980-A2 | Derivatives of substituted N-alkyl imidazoles, their preparation and these compounds for pharmaceutical use | SYNTEX (U.S.A.) INC. (US) | 1979-12-12 | — | — | EP | disclosed |
| US-4078071-A | FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4045568-A | FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | CYP19A1 884/4885CYP11B1 61/4885CYP11B2 68/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP19A1 641/4885CYP11B1 63/4885CYP11B2 60/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP19A1 641/4885CYP11B1 63/4885CYP11B2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.